New Insights into Neuromyelitis Optica

Woojun Kim, Su-Hyun Kim, Ho Jin Kim
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea

Neuromyelitis optica (NMO) is an idiopathic inflammatory disorder of the central nervous system (CNS) that preferentially affects the optic nerves and spinal cord. In Asia, NMO has long been considered a subtype of multiple sclerosis (MS). However, recent clinical, pathological, immunological, and imaging studies have suggested that NMO is distinct from MS. This reconsideration of NMO was initially prompted by the discovery of a specific antibody for NMO (NMO-IgG) in 2004. NMO-IgG is an autoantibody that targets aquaporin-4 (AQP4), the most abundant water channel in the CNS; hence, it was named anti-AQP4 antibody. Since it demonstrated reasonable sensitivity and high specificity, anti-AQP4 antibody was incorporated into new diagnostic criteria for NMO. The spectrum of NMO is now known to be wider than was previously recognized and includes a proportion of patients with recurrent, isolated, longitudinally extensive myelitis or optic neuritis, and longitudinally extensive myelitis or optic neuritis associated with systemic autoimmune disease or with brain lesions typical of NMO. In this context, a new concept of “NMO spectrum disorders” was recently introduced. Furthermore, seropositivity for NMO-IgG predicts future relapses and is recognized as a prognostic marker for NMO spectrum disorders. Humoral immune mechanisms, including the activation of B-cells and the complement pathway, are considered to play important roles in NMO pathogenesis. This notion is supported by recent studies showing the potential pathogenic role of NMO-IgG as an initiator of NMO lesions. However, a demonstration of the involvement of NMO-IgG by the development of active immunization and passive transfer in animal models is still needed. This review focuses on the new concepts of NMO based on its pathophysiology and clinical characteristics. Potential management strategies for NMO in light of its pathomechanism are also discussed.

Key Words neuromyelitis optica, Devic’s disease, neuromyelitis optica spectrum disorder, pathogenesis, diagnosis, management.

Introduction

Neuromyelitis optica (NMO, also known as Devic’s disease) is an idiopathic inflammatory syndrome of the central nervous system (CNS) that is characterized by severe attacks of optic neuritis (ON) and myelitis.1 NMO was first described in 1870 by T. Clifford Allbutt, who reported an association between myelitis and unilateral optic nerve disorder.2 In 1894, Eugène Devic coined the term “neuromyelite optique aigue” (acute optic neuromyelitis) to describe 16 patients who had lost vision unilaterally or bilaterally and within weeks developed severe spastic paraparesis or tetraparesis, loss of sensation, and often loss of sphincter control. These symptoms were recognized as resulting from inflammation affecting both the optic nerves and the spinal cord.3 For the next 100 years, NMO was considered to be a monophasic, devastating disorder that affected the optic nerves and the spinal cord, but spared the remainder of the CNS.

There has long been controversy as to whether NMO is a variant of multiple sclerosis (MS) or a distinct disease. A landmark advance in this regard was the identification of a disease-specific autoantibody, NMO-IgG, in the serum of patients with NMO.4 NMO-IgG binds selectively to aquaporin (AQP)-4 (AQP4), a water channel that is densely expressed in astrocytic foot processes at the blood-brain barrier (BBB).5 This finding has prompted revisions of the diagnostic criteria for NMO6 and facilitated an appreciation for the wide spectrum of this
disorder, which includes a proportion of patients with recurrent, isolated, longitudinally extensive myelitis (LEM) or ON, and LEM or ON associated with systemic autoimmune disease or with brain lesions typical of NMO. Thus, the concept of “NMO spectrum disorders” (NMOSDs) was introduced. In recent years, the clinical spectrum, immunological/pathological profiles, and management issues regarding NMO or NMOSDs have been better characterized. This review focuses on the new concepts of NMO based on its pathophysiology and clinical characteristics. Potential management strategies for NMO, in light of its pathomechanism, are also discussed.

Epidemiology and Genetic Predisposition

While there have been few relevant population-based studies, the prevalence of NMO has been estimated by its frequency relative to MS, and has been estimated at 1 per 100,000 population.14 In a retrospective, cross-sectional study performed in Italy, the prevalence of NMOSDs was 1.5%, with a ratio of 42 MS cases to 7 NMOSD cases.15 However, the proportion of cases with a non-Caucasian background is significantly greater. NMO is believed to be linked to 30-40% of MS cases in Japanese,16 16.8% in African-Americans,17 and 15% in African-Brazilians.18 NMO predominantly affects females, with a female-to-male ratio of 9:1. The median age at onset of NMO is the late 30s;19 however, there have been several reports of NMO cases in childhood20-25 and in the elderly.19 NMO is not generally considered to have a familial tendency.14 However, genetic susceptibility is possible, since the reported incidence of familial cases of NMO appears to be higher than expected based on its frequency in the general population.20-25

NMO was reported to be associated with the human leukocyte antigen DPB1*0501 allele in the Japanese,26-27 but further analysis of patients with pure optocarpinal MS (OSMS) who had consistently normal brain magnetic resonance imaging (MRI) scans suggested that OSMS is not necessarily associated with DPB1*0501.28 DPB1*0501 was recently reported to be associated with NMO in the Han population of southern China.29

Immunopathology

Pathology of NMO lesions

The pathology of NMO lesions was initially described from autopsied cases by Lucchinetti et al.30 Extensive demyelination was found to be present across multiple spinal cord levels and was associated with cavitation, necrosis, and acute axonal pathology (spheroids), in both the gray and white matter. There was a marked loss of oligodendrocytes within the lesions. The inflammatory infiltrates in active lesions were characterized by extensive macrophage infiltration associated with large numbers of perivascular granulocytes and eosinophils, and a few T cells. There was pronounced perivascular deposition of immunoglobulins (mainly IgM) and complement C9 neo antigen in active lesions associated with prominent vascular fibrosis, and hyalinization in both the active and inactive lesions. These findings support a role for humoral immunity in the pathogenesis of NMO.

Discovery of NMO-IgG

In 2004, an antibody that reacted specifically with mouse brain was identified in the serum of NMO patients.4 This antibody, named NMO-IgG, was present in the CNS microvessels, pia, subpia, and Virchow-Robin spaces, and was partly colocalized with laminin. This tissue-based indirect immunofluorescence assay (IIFA) was sensitive (73%) and highly specific (91%) to NMO. NMO-IgG was also detected in about half of patients with syndromes that placed them at high risk for NMO, such as idiopathic isolated recurrent ON or LEM. During the following year, the same researchers proved that AQP4 is the target antigen of NMO-IgG by showing that NMO-IgG binds selectively to AQP4-transfected human embryonic kidney (HEK)-293 cells.5

AQPs and AQP4

AQPs are water-channel proteins that assemble as homotetramers in cell membranes and play a major role in fluid homeostasis. AQP4 is one of 13 members of the AQP family (AQP0-AQP12) present in mammals and is the predominant AQP in the brain.31 AQP4 is found throughout the brain, but is particularly abundant in the optic nerves and spinal cord.32 Other organs that contain AQP4 include the lung, skeletal muscle, stomach, inner ear, and kidney.33 In rats, AQP4 is present on astrocytic foot processes along the endothelial tight junctions at the BBB, on the abluminal side of cerebral microvessels, within the cerebellar Purkinje cell layer, and in the hypothalamus.34

AQP4 exists in two isoforms, M1 (34 kDa) and M23 (32 kDa), both of which function as water channels and form stable tetramers. The relative abundances of the AQP4 isoforms vary with the tissue type, with the rat brain containing approximately three AQP4-M23 proteins per one AQP4-M1 protein. Freeze-fracture electron microscopy of cells transfected with AQP4-M1 versus AQP4-M23 has demonstrated that only the M23 form assembles into large orthogonal arrays of more than 100 particles; AQP4-M1 tetramers were largely dispersed and only occasionally formed small arrays of fewer than 12 particles.35 There remains a controversy regarding which isoform is the major target of the AQP4 antibody (AQP4-Ab). A
study employing Western blotting found AQP-M1 to be the specific target of the AQP4-Ab. However, in another study using cell-based IIFA, the sensitivity with AQP4-M1 transfected cells was lower for NMO (70%) and high-risk NMO (39%), suggesting that NMO-IgG targets mainly AQP4-M23.

**Role of AQP4-Ab in the pathogenesis of NMO**

There is a series of clinical studies showing that AQP4-Ab participates in the pathogenesis of NMO and that AQP4-Ab may be predictive of relapse and/or later conversion to definite NMO. Among 23 patients with LEM (14 seronegative and 9 seropositive) followed for 1 year, none of the seronegative patients experienced a relapse or developed ON, whereas 5 of the seropositive patients experienced a second event: 4 (44%) developed recurrent myelitis and 1 (11%) developed ON. Similarly, among 12 seropositive ON patients for whom long-term follow-up was possible, 6 (50%) experienced an episode of myelitis and fulfilled the diagnostic criteria for NMO. Furthermore, the final visual score of seropositive patients was worse than that of seronegative patients.

AQP4-Ab titers also appear to be correlated with disease activity. In a cross-sectional study of 148 Japanese patients, higher antibody titers measured with a semiquantitative cell-based assay were associated with complete blindness and extensive or large cerebral lesions on MRI. The length of spinal cord lesions on MRI was positively correlated with the antibody titer at the nadir of exacerbation. AQP4-Ab titers decreased after high-dose methylprednisolone, and a follow-up showed that the antibody titers remained low during relapse-free periods under immunosuppression. In our experience, the AQP4-Ab levels measured by enzyme-linked immunosorbent assay (ELISA) changed with disease activity. Of 38 NMOSD patients who were initially seropositive, 21 became seronegative under effective immunosuppressive therapy, and 17 continued to be seropositive. During most relapses, the serum AQP4-Ab levels were either higher or increasing compared with previous levels. However, rising antibody levels did not always lead to acute exacerbation. Among 13 patients who were initially seronegative, 2 converted to seropositivity following acute exacerbation. In a study involving eight NMO-IgG positive patients, a fluoroimmunoprecipitation assay revealed that relapses were preceded by an increase in antibody titer of up to threefold, which was paralleled by a rise in other serum autoantibodies in only one patient. Moreover, AQP4-Ab titers correlated with CD19+ cell counts during therapy with rituximab. Treatment with immunosuppressants resulted in markedly reduced antibody levels and relapse rates. Together these results suggest that NMO and high-risk syndrome are associated with AQP4-Ab titer, and that this antibody titer has significant clinical and immunological implications in NMO.

Pathological data also support the existence of a relationship between AQP4-Ab and NMO pathogenesis. In acute and chronic NMO lesions, AQP4 immunoreactivity was lost, and glial fibrillary acidic protein (GFAP) staining was decreased. Myelin basic protein (MBP)-stained myelinated fibers were relatively preserved, despite the loss of AQP4 and GFAP staining. The areas surrounding the lesions in NMO exhibited enhanced expression of AQP4 and GFAP, reflecting reactive gliosis. These features in NMO are distinct from those of MS and suggest that astrocytic impairment is associated with the loss of AQP4.

In an *in vitro* study, AQP4-Ab bound to AQP4-expressing cells, activated human and rabbit complement, and caused plasma cell membrane lysis. In a study using AQP4-expressing HEK-293 cells, serum IgG (predominantly IgG1) from patients with NMO bound to the extracellular domain of AQP4 and initiated two potentially competing outcomes: AQP4 endocytosis/degradation and complement activation.

NMO-IgG binding to human fetal astrocytes has been found to alter the polarized expression of AQP4 and increase the permeability of the human BBB. The binding of NMO-IgG to human fetal astrocytes was demonstrated to induce degranulation of natural killer cells, astrocyte killing by antibody-dependent cellular cytotoxicity, and complement-dependent granulocyte attraction. The AQP4-Ab-induced astrocytopathy was shown to occur via necrosis rather than apoptosis.

In contrast, neurons and myelin appear to be preserved at the initiation of the inflammatory process. In line with pathological findings, Takano et al. recently reported a prominent elevation of cerebrospinal fluid (CSF)-GFAP during the acute phase of NMO, but only a modest elevation of CSF-MBP. De-myelination may occur secondarily by excitotoxicity due to impaired glutamate homeostasis. Hinson et al. found that patient serum and active complement compromised the membrane integrity of CNS-derived astrocytes. Without complement, astrocytic membranes remained intact, but AQP4 was endocytosed, with the concomitant loss of Na+-dependent glutamate transport by excitatory amino acid transporter, resulting in the deterioration of glutamate homeostasis.

**Animal studies of NMO**

Several studies have employed animal models of NMO. IgG obtained from NMO patients was injected intraperitoneally into a rat with experimental autoimmune encephalomyelitis (EAE), and the passive transfer of NMO-IgG exacerbated the neurologic deficit. The active lesions of the rats exhibited pathological characteristics similar to those of NMO, including loss of astrocytes and perivascular deposition of immunoglobulin and complement. Interestingly, GFAP was rel-
NMO has occasionally been associated with other autoimmune diseases, including hypothyroidism, Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), pernicious anemia, ulcerative colitis, primary sclerosing cholangitis, rheumatoid arthritis, mixed connective tissue disorders, and idiopathic thrombocytopenic purpura. Neuronal and muscle antibodies commonly coexist with NMO and its marker, NMO-IgG. Muscle acetylcholine receptor antibodies were detected in 13% of NMO patients. Several cases with NMO and myasthenia gravis were also reported. Non-organ-specific autoantibodies such as antinuclear antibodies or SS-A antibodies were often found in patients with NMO or NMOSDs. However, NMO-IgG is highly specific to NMO and does not occur in many other conditions that have been studied as control diseases with alternative causes for severe myelopathy (e.g., documented viral myelitis, vitamin B12 deficiency, sarcoidosis, and tumor) or optic neuropathy (e.g., ischemic or compressive ON). Therefore, NMOSDs with seropositive findings for NMO-IgG occurring with SS/SLE or non-organ-specific autoantibodies are indications of coexisting NMO, rather than vasculopathic or other complications of SS/SLE.

Clinical, Imaging, and Laboratory Features

Clinical features
NMO patients can have a monophasic or relapsing course. Although a monophasic course of acute transverse myelitis simultaneously associated with ON is classical, more than 90% of patients experience a relapsing course. ON can be separated from transverse myelitis by months or years, and episodes tend to relapse, with significant accumulation of disability. Among patients who developed a relapsing course, 55% had experienced their first optic nerve or spinal cord relapse within 1 year, 78% within 3 years, and 90% within 5 years.

Predictors of a relapsing course are a longer interattack interval between the first two clinical events, older age at onset, female gender, and less severe motor impairment with the
sentinel myelitis event. A history of other autoimmune diseases, higher attack frequency during the first 2 years of the disease, and better motor recovery following the index myelitis event are associated with mortality due to relapsing NMO. Final assessments of visual acuity, motor strength, and sensory function were worse in the relapsing group than in the monophasic group. A simple clinical observation that should suggest NMO is the attack severity; individual ON and myelitis attacks are more severe in NMO compared with MS, and the recovery is less complete. Prominent dysestheteic, radicular pain, possibly associated with Hermitte’s symptom, is common and occurs in up to 35% of acute severe myelitis attacks in relapsing NMO. Respiratory failure caused by acute cervical myelitis can also be associated with NMO. In a study performed in the late 1990s, 33% of relapsing patients and 9% of monophasic patients experienced respiratory failure. The 5-year survival rates were 90% in the monophasic group and 68% in the relapsing group. All deaths in the relapsing group resulted from respiratory failure.

NMO has traditionally been regarded as a disease without brain involvement, and a negative brain MRI at disease onset has been considered a major supportive criterion for the diagnosis of NMO. However, NMO is not confined to the spinal cord or optic nerves. In fact, patients who present with brain symptoms at their first manifestation are not rare. We found that 15 of 83 NMOSD patients presented with brain symptoms. Their initial brain manifestations were classified into two groups according to clinical characteristics: 1) encephalopathy mimicking acute disseminated encephalomyelitis or posterior reversible encephalopathy syndrome, and 2) characteristic brainstem symptoms such as intractable hiccup and vomiting. Most of the brain symptoms and lesions resolved. Pediatric NMO, in particular, has diverse clinical presentations. Patients can present with cerebral symptoms such as encephalopathy, aphasia, or seizure. Intractable hiccup and nausea are symptoms unique to relapsing NMO and are associated with a linear medullary or medullospinal lesion involving the pericentral region, the area postrema, and the nucleus tractus solitarius, which are sites of high AQP4 expression. Since those lesions were not detected in MS cases, a linear medullary lesion causing intractable hiccup and nausea may distinguish NMO from MS.

Imaging characteristics

Brain MRI and orbit MRI often reveal gadolinium enhancement of the optic nerve during an acute attack of ON. A spinal cord MRI, when performed within days or weeks after an acute myelitis attack, is very likely to show a central cord lesion that extends over three or more vertebral segments. Atrophy and central cavitation are seen in later stages of the disease. The manifestation of a longitudinally extensive lesion (on at least three vertebral segments) on spinal cord MRI is one of the most specific neuroimaging findings for NMO, with high sensitivity (98%) and specificity (83%). However, MRI lesions are subject to timing issues; a lengthy T2-weighted lesion might not have developed fully in the first few days after clinical symptom onset, or it might have contracted or resolved over time.

Several studies have found asymptomatic and symptomatic brain lesions in NMO that were clearly distinct from the lesions in MS. Lesions were observed on brain MRI in 60-88% of patients during follow-up. Asymptomatic lesions are more common, although symptomatic brain involvement is not rare in NMO. In our study analyzing brain MRIs of 78 Korean NMOSD patients who were seropositive for AQP4-Ab, 45% had symptomatic brain involvement. Brain lesions were identified on MRI at first presentation in 24 of 49 patients (49%), and most patients (83%) exhibited abnormalities on brain MRI during the disease course. The localization and configuration of the lesions were unique; the characteristic brain lesions were 1) lesions involving corticospinal tracts such as the posterior limb of internal capsule and cerebral peduncle (44%), 2) extensive hemispheric lesions probably due to vasogenic edema (29%), 3) periependymal lesions surrounding the aqueduct and the third and fourth ventricles (22%), 4) periependymal lesions surrounding the lateral ventricles (40%), and 5) medullary lesions, often contiguous with cervical lesions (31%). The brain lesions adjacent to the ventricular system mirror the periventricular and hypothalamic localization of AQP4. The extensive hemispheric lesions differed from those observed in regions of high AQP4 expression and were likely related to vasogenic edema; they sometimes looked like “spilled ink” and followed the white-matter tracts. This assumption was supported by diffusion-weighted images and apparent diffusion coefficient maps, which both exhibited a high signal intensity without gadolinium enhancement and were likely related to vasogenic edema; they sometimes looked like “spilled ink” and followed the white-matter tracts. Enhancement on brain MRI is one of the most specific neuroimaging findings for NMO, with high sensitivity (98%) and specificity (83%). However, MRI lesions are subject to timing issues; a lengthy T2-weighted lesion might not have developed fully in the first few days after clinical symptom onset, or it might have contracted or resolved over time.

Laboratory findings

Several methods have been developed to test for NMO-IgG or AQP4-Ab; these include tissue-based IIFA and cell-based IIFA, radioimmunoprecipitation assays, fluoroimmunoprecipitation assays, ELISA, flow cytometry, and Western blot analysis. All showed good specificity (91-100%) for relapsing NMO, but the sensitivities varied widely (27-91%).
In our experience using ELISA, AQP4-Ab levels and even serostatus varied during follow-up. Therefore, negative test results cannot rule out the diagnosis of NMO or an NMOSD, and repeated testing is needed. An analysis of the CSF during the acute phase may help to distinguish between NMO and MS. A previous study found pleocytosis [white blood cell count (WBC) >5 cells/mm³] to be present in 11 of 15 monophasic patients (73%) and in 31 of 38 relapsing patients (82%). WBCs higher than 50 cells/mm³ were observed in 5 of 14 patients (36%) in the monophasic group and 13 of 38 patients in the relapsing group (34%). Relapsing NMO is characterized by a rarity of oligoclonal IgG bands and the presence of a normal IgG index, whereas oligoclonal IgG bands are seen in 70-90% of MS patients in Western countries.

### Diagnosis

Many NMOSD patients develop severe, irreversible impairment early in the disease, making early diagnosis critical for effective long-term treatment to prevent attacks. In 1999, Wingerchuck et al. proposed the first diagnostic criteria for NMO. The major criteria included three absolute requirements: ON, acute myelitis, and no symptoms implicating other CNS regions. To enhance the diagnostic specificity, at least one of three minor supportive criteria should be met: 1) brain MRI at disease onset appearing normal or not fulfilling MS imaging criteria, 2) spinal cord MRI showing a lesion extending over at least three vertebral segments, and 3) CSF pleocytosis [WBC >5 cells/mm³] or ≥5 neutrophils/mm³. Alternatively, the presence of two of the three minor supportive criteria plus bilateral ON, severe residual visual loss, or severe, fixed, postattack weakness was sufficient.

After identifying NMO-IgG, revised diagnostic criteria for definite NMO were proposed. These included ON, myelitis, and at least two of the following three supporting criteria: 1) MRI evidence of a contiguous spinal cord lesion extending over at least vertebral segments, 2) brain MRI at onset non-diagnostic for MS, and 3) NMO-IgG seropositivity (Table 1). CNS involvement beyond the optic nerves and spinal cord is compatible with NMO. This diagnostic combination was 99% sensitive and 90% specific for NMO. An international task force recently recommended diagnostic criteria for NMO that included more detailed criteria for brain MRI results (Table 2).

After several reports describing NMO-IgG seropositivity in up to 60% of cases with LEM, necrotic myelopathy, and recurrent ON, the spectrum of disorders classified as NMO was expanded and now includes the variants summarized in Table 3.

### Table 1. Revised criteria for the diagnosis of NMO

| Optic neuritis | Acute myelitis |
|----------------|---------------|
| At least two of the following three supportive criteria: | |
| Contiguous spinal cord MRI lesion extending over at least three vertebral segments | |
| Onset brain MRI not meeting the diagnostic criteria for MS | |
| NMO-IgG seropositivity status | |

NMO: neuromyelitis optica; MS: multiple sclerosis.

### Table 2. Diagnostic criteria of NMO

| Major Criteria [all criteria are required, but may be separated by an unspecified interval] |
|-----------------------------------------------|
| 1) Optic neuritis in one or more eyes |
| 2) Transverse myelitis, clinically complete or incomplete, but associated with radiological evidence of spinal cord lesion extending over three or more spinal segments on T2-weighted MRI images and hypointensity on T1-weighted images when obtained during acute episode of myelitis |
| 3) No evidence for sarcoidosis, vasculitis, clinically manifest systemic lupus erythematosus or Sjögren’s syndrome, or other explanation for the syndrome. |

**Minor criteria [at least one must be fulfilled]**

1. Most recent brain MRI scan of the head must be normal or may show abnormalities not fulfilling Barkhof criteria used for McDonald diagnostic criteria, including:
   1) Non-specific brain T2 signal abnormalities not satisfying Barkhof criteria as outlined in McDonald criteria
   2) Lesions in the dorsal medulla, either in contiguity or not in contiguity with a spinal cord lesion
   3) Hypothalamic and/or brainstem lesions
   4) "Linear" periventricular/corpus callosum signal abnormality, but not avoid, and not extending into the parenchyma of the cerebral hemispheres in Dawson finger configuration

2. Positive test in serum or CSF for NMO-IgG/aquaporin-4 antibodies

*These criteria exclude limited or inaugural syndromes that may be NMO, such as recurrent transverse myelitis with longitudinally extensive spinal cord lesions, or recurrent ON: further study is warranted to clarify their relationship with NMO, especially in the setting of seropositivity for NMO-IgG/AQP4 antibodies. Periodic surveillance with brain MRI scanning is necessary to monitor for the emergence of new lesions that may lead to a revised diagnosis. NMOSD: neuromyelitis optica, CSF: cerebrospinal fluid.
Management

The optimal treatment for NMO has not yet been established, because no randomized controlled trials have been performed. Thus, treatment recommendations are based on small-sized case series, case reports, or even individual clinical observations.

Acute-phase treatment

High-dose corticosteroids

For acute attacks, the traditional treatment is intravenous methylprednisolone at 1,000 mg/day for 3-5 consecutive days. This recommendation is taken from studies of MS and idiopathic ON; no controlled therapeutic trials have investigated the effectiveness of steroids specifically in NMO. Experience has indicated the need to continue steroids in the form of oral prednisone, with slow tapering over months in the relapsing form of the disease. Without tapering, patients tend to relapse within weeks after an acute attack. Wingerchuck et al. reported that 55 of 69 NMO patients with acute attacks showed improvement after high-dose corticosteroid treatment. In cases with an unsatisfactory response, a repeated course of corticosteroids may be considered.

Therapeutic plasmapheresis

A small proportion of patients fail to improve with high-dose corticosteroid therapy, and their prognosis can become grave. In such cases, therapeutic plasmapheresis should be considered. The removal of circulating autoantibodies, immune complexes, cytokines, and other inflammatory mediators is thought to be the principal mechanism of action for plasmapheresis. Plasmapheresis treatments include conventional plasma exchange using centrifugation, double-filtration plasmapheresis, cryofiltration, and immunoadsorption. Most previous studies have used conventional plasma exchange.

Favorable outcomes have been obtained following therapeutic plasma exchange for severe relapses of conventional MS and other devastating demyelinating disorders such as acute myelitis, acute disseminated encephalomyelitis (ADEM), NMO, and recurrent myelitis. However, there is a dearth of data for NMO, because most previous studies have included a broad spectrum of CNS demyelination patients with only a few cases of NMO. In a retrospective study of 59 consecutive patients that included 22 MS, 10 NMO, and 10 AD-EM patients, therapeutic plasma exchange was followed by moderate or marked functional improvement in 44.1% of the treated patients, which included 60% of the NMO patients. Seven of ten patients with severe isolated ON who were unresponsive to high-dose corticosteroids showed improvement of visual acuity, although their NMO-IgG or AQP4-Ab levels were not measured. In a study by Watanabe et al., six NMO-IgG-positive patients (three with ON and three with myelitis) who were unresponsive to high-dose intravenous methylprednisolone received plasma exchange (three to five exchanges, each comprising 2-3 L), and three (one with ON and two with myelitis) experienced a definite functional improvement. Clinical improvement started to appear after one or two exchanges. A retrospective study by Bonnan et al. included 96 severe spinal attacks in 43 Afro-Caribbean patients. As an add-on therapy for 29 attacks, plasma exchange was given daily for 5 days, with the exchange of one volume of plasma with 5% albumin solution. The plasma-exchange-treated group showed improvements in neurological deficits.

Factors associated with moderate or marked improvement with plasma exchange were male gender, preserved reflexes, and early initiation of treatment. In addition, early initiation of plasma exchange and improvement at discharge were significantly associated with response at 6 months. Minor adverse events related to treatment in the course of plasma-exchange sessions were deep hypofibrinogcnemia, hematoma at the puncture site, benign vagal reaction, asymptomatic bacteremia, abdominal syndrome, and extreme bradycardia. Patients should be closely monitored for the usual risks associated with long-lasting immobility secondary to severe myelitis attacks, including thromboembolic events and respiratory/urinary tract infections.

In guidelines established by the European Federation of Neurological Societies, early initiation of a rescue therapy with plasmapheresis is indicated in cases that are unresponsive to high-dose corticosteroids, with up to seven treatments every other day. Therapeutic plasma exchange with seven exchan-

Table 3. NMO spectrum

| NMO | Limited form of NMO |
|-----|-------------------|
|     | Idiopathic single or recurrent events of longitudinally extensive myelitis (≥3 vertebral segment spinal cord lesions seen on MRI) |
|     | Optic neuritis: recurrent or simultaneous bilateral |
|     | Asian optic-spinal multiple sclerosis |
|     | Optic neuritis or longitudinally extensive myelitis associated with systemic autoimmune disease |
|     | Optic neuritis or myelitis associated with brain lesions typical of NMO [hypothalamic, corpus callosal, periventricular, or brainstem] |

NMO: neuromyelitis optica.
ges of approximately 55 mL/kg each, administered every other day for 14 days, should be considered. However, larger-scale studies are needed to determine the optimal number of plasma exchanges.

A trial of double-filtration plasmapheresis for NMO-IgG-positive patients was recently reported. In contrast to conventional plasma exchange, which uses one plasma separator filter, double-filtration plasmapheresis uses two types of separator filter. The second filter selectively removes high-molecular-weight proteins, including inflammatory cytokines. Eight patients were treated with double-filtration plasmapheresis for a maximum of seven times per month for 3 months, and 3,000-4,000 mL of plasma were exchanged at each session. Six of the eight patients (75%) showed therapeutic improvement after double-filtration plasmapheresis treatment, with improvements of vision (two patients), movement (seven patients), and sensory function (four patients). However, the clinical status of the patients, especially whether they were in acute relapse, was not described.

**Intravenous immunoglobulin**

Intravenous immunoglobulin (IVIg) has been used for the treatment of autoimmune disorders including autoimmune thombocytopenia, chronic inflammatory demyelinating polyradiculoneuropathy, and Guillain-Barré syndrome. The best-understood actions of IVIg include 1) modulation of pathogenic autoantibodies, 2) inhibition of complement activation and interception of membranolytic attack complex formation, 3) modulation of the inhibitory or activation Fc receptors on macrophages invading targeted tissues in nerve and muscle, 4) down-regulation of pathogenic cytokines and adhesion molecules, 5) suppression of T-cell functions, and 6) interference with antigen recognition. Considering the autoimmune mechanisms in the pathogenesis of NMO, IVIg could be a candidate treatment for NMO. However, IVIg has not yet been evaluated specifically for relapses of NMO and is rarely used for corticosteroid-refractory attacks.

**Prevention of relapses**

Many patients with NMO were initially diagnosed as having MS, and treated with approved immunomodulatory therapies such as IFN-β and glatiramer acetate. However, exacerbations of severe ON and myelitis have been reported with IFNβ-1b treatment in Japanese OSMS patients. IFNβ-1a treatment was recently reported to have increased AQP4-Ab levels in a case of NMO.

**Azathioprine**

Azathioprine, a purine antimetabolite, interferes with the proliferation of cells, and especially leukocytes, and is commonly used as an immunosuppressive drug in the treatment of MS. Azathioprine (2-3 mg/kg/day), usually in combination with oral prednisone (1 mg/kg/day), is widely employed as a preventative therapy. In an observational case series, newly diagnosed NMO patients received a maintenance combination treatment of prednisone (1 mg/kg/day) and azathioprine (2-3 mg/kg/day), with a gradual reduction of the prednisone dose after 2 months. The patients remained stable, with no attacks, for at least 18 months, and their disability scores improved significantly. Gastrointestinal complaints and leukopenia are the most frequently reported adverse effects of azathioprine therapy, and occur in more than 10% of patients. Infections, allergy, anemia, thrombocytopenia, and pancytopenia are also common. Most of these adverse effects are easily managed by dosage adjustment or therapy interruption; however, the risk for cancer increases with the treatment duration and cumulative dose.

**Low-dose corticosteroids**

The results of a retrospective study suggested that there was a beneficial effect of low-dose corticosteroid monotherapy in reducing the incidence of relapse in NMO. The annual relapse rate was significantly lower during corticosteroid monotherapy than during the period without corticosteroid therapy. Relapses occurred significantly more often with corticosteroid doses of ≤10 mg/day than with doses of >10 mg/day. However, long-term treatment with corticosteroids often causes various complications.

**Mycophenolate mofetil**

Mycophenolate mofetil (MMF) is a noncompetitive inhibitor of the enzyme inosine 5-monophosphate dehydrogenase. It controls lymphocyte proliferation and T-cell-dependent antibody responses by inhibiting purine synthesis. The lymphocyte-selective inhibitory effect of MMF presents an advantage over azathioprine. In a case report of a 9-year-old girl who had a severe relapsing-remitting course of NMO despite treatment with azathioprine and corticosteroid, a dramatic and sustained improvement occurred over a 2-year period of treatment with MMF. In a retrospective case series with prospective telephone follow-up, 24 patients with NMOSD were treated with MMF (median dose, 2,000 mg/day). The median annualized relapse rate was lower after treatment than before treatment, and disabilities stabilized or decreased in 22 of 24 patients (91%). MMF is well tolerated in general, and its typical side effects involve the gastrointestinal (diarrhea, nausea, vomiting, and abdominal cramps), hematologic (leukopenia, anemia, and thrombocytopenia), and genitourinary (urgency, frequency, dysuria, and sterile pyuria) systems. In contrast to azathioprine, MMF does not induce nephrotoxici-
ty, hepatotoxicity, or significant bone-marrow suppression.\textsuperscript{116}

\textbf{Mitoxantrone}

Mitoxantrone hydrochloride is an anthracyclene antineoplastic agent that has been approved as a treatment for secondary progressive and worsening relapsing-remitting MS. Mitoxantrone potentially suppresses Th lymphocytes and the humoral immune system via both macrophage and B-cell attenuation.\textsuperscript{117} It has been suggested that monthly intravenous infusion of mitoxantrone at 12 mg/m\textsuperscript{2} for 6 months followed by three additional treatments every 3 months is effective for the prevention of NMO relapses. Among five patients enrolled in a study of mitoxantrone treatment, two patients relapsed once within the initial 5 months of treatment, and clinical improvement was seen on MRI in four patients.\textsuperscript{118}

In our experience with 20 frequently relapsing NMO patients, the median annualized relapse rate was reduced by 75%, and 50% of patients became relapse-free during mitoxantrone treatment. Disability improved or stabilized in all patients. No patients had serious adverse effects during the mean follow-up period of 41 months after completing the therapy. Flow cytometric analysis of cell-surface markers revealed that mitoxantrone treatment preferentially affected CD27\textsuperscript{+}CD19\textsuperscript{+} memory B cells.\textsuperscript{119}

Common adverse effects of mitoxantrone include leukopenia, amenorrhea, elevated liver enzyme levels, nausea, alopecia, bluish discoloration of the urine, and urinary tract infections. The most serious adverse consequences of mitoxantrone treatment, which occur infrequently, are cardiotoxicity, acute leukemia, and severe infection. The total dose of mitoxantrone should be limited to a cumulative dose of 100 mg/m\textsuperscript{2}, since high doses have the potential to cause cardiotoxicity.\textsuperscript{120}

One study found that therapy-related acute leukemia occurred in 0.3\% of patients, and the median onset was at 18.5 months (range, 40-60 months) after the start of mitoxantrone treatment: among the 25 patients for which outcomes were reported, 6 died (24\%). A relationship between total mitoxantrone dose and acute leukemia is suggested, given that more than 80\% of the patients who developed acute leukemia had received >60 mg/m\textsuperscript{2}.\textsuperscript{121}

\textbf{Intravenous immunoglobulin}

There are two reports regarding IVIg for the preventive therapy of NMO. Two NMO patients with frequent attacks that were unresponsive to daily corticosteroids and azathioprine experienced no further attacks and showed improved neurological status after monthly IVIg infusion; 60 g in one patient and initially 0.4 g/kg/day for 5 days followed by 1.0 g/kg/day over 2 consecutive days per month for the other patient.\textsuperscript{122}

In the other report, a female NMO patient treated with monthly IVIg infusion (0.4 g/kg/day for 1 day) did not experience a relapse for more than 4 years, and her neurologic status also improved during follow-up.\textsuperscript{123} Further studies assessing the effectiveness and safety of IVIg as a relapse-preventing therapy for NMO are needed.

\textbf{Rituximab}

Since NMO is related to humoral immunity, rituximab may be an effective treatment option. Rituximab is a chimeric, murine/human monoclonal antibody directed against the CD20 antigen expressed on pre-B cells and mature B cells. It causes depletion of B cells when administered \textit{in vivo}. The possibility of rituximab as a therapy for NMO was first suggested by the results of an open-label study in which eight consecutive patients received four intravenous infusions of rituximab at 375 mg/m\textsuperscript{2}, administered once per week.\textsuperscript{124} When the patients’ peripheral B-cell counts became detectable by fluorescence-activated cell sorting, they were given the option of repeated rituximab treatment. Six of the eight patients became relapse free, and the median attack rate declined dramatically. Seven patients experienced substantial recovery of neurological function during the follow-up period, which averaged 1 year.

In a retrospective analysis of 25 patients with NMO who were treated with rituximab,\textsuperscript{125} two rituximab regimens were used: 1) 375 mg/m\textsuperscript{2} infused once per week for 4 weeks (n=18), and 2) 1,000 mg infused twice, with a 2-week interval between infusions (n=4). The median annualized pretreatment relapse rate was 1.7, and the rate dropped to 0 at a median follow-up of 19 months. Disability improved or stabilized in 80\% of the patients. Two patients died during the follow-up period, one from a brainstem relapse and one due to suspected septicemia.

We recently completed a study of rituximab treatment in 30 NMOSD patients.\textsuperscript{126} The treatment protocol consisted of induction therapy (375 mg/m\textsuperscript{2} once weekly for 4 weeks, or 1,000 mg infused twice, with a 2-week interval between infusions), followed by maintenance therapy. The maintenance therapy was a single dose of rituximab at 375 mg/m\textsuperscript{2} administered whenever re-emerging CD27\textsuperscript{+} memory B cells represented more than 0.05\% of peripheral blood mononuclear cells. Of the 30 NMOSD patients, 29 showed a marked reduction in relapse rate after 24 months of rituximab treatment. The relapse rate was reduced significantly by 58\%, and 70\% of the patients became relapse-free over 24 months. Disability either improved or stabilized in 97\% of the patients. AQP4-Ab levels declined significantly following treatment with rituximab, consistent with the clinical response and the effect on CD27\textsuperscript{+} memory B cells.

The side effects of rituximab include fever, chills, headache, asthenia, hypotension, bronchospasm, urticaria, and leukope-
nia. It has also been associated with progressive multifocal leukoencephalopathy, which was reported in three patients treated for rheumatoid arthritis and two treated for SLE. However, these patients had also received other immunosuppressive agents prior to or in conjunction with rituximab. The long-term side effects are uncertain.

**Intermittent plasma exchange**

The therapeutic efficacy of intermittent plasma exchange (double-filtration plasmapheresis or conventional plasma exchange) in combination with immunosuppressants to prevent recurrence was evaluated in two NMO patients, and the recurrence rate was significantly reduced after intermittent plasma exchange.  

**Conclusion**

Recent advances in clinical, neuroimaging, laboratory, and pathological hallmarks have established that NMO is a disease that is distinct from MS. Numerous clinical and experimental studies have implicated AQP4-Ab-mediated autoimmunity in the pathogenesis of NMO and provided a strong rationale for the use of therapies targeting humoral immunity in NMO. The development of the AQP4-Ab test has led to the recognition of atypical presentations of NMO that are beyond the traditional view. These new insights into NMO enable us to make an early diagnosis of NMO and to apply appropriate immunotherapies in a wider spectrum of NMO patients.

A future avenue of investigation could include seronegative NMO, genetic susceptibility factors, and the development of surrogate markers for clinical efficacy and of promising animal models of NMO. An improved understanding of NMO will lead to the identification of an optimal treatment strategy for this debilitating disease.

**Conflicts of Interest**

The authors have no financial conflicts of interest.

**Acknowledgements**

This study was supported by grant A080588-28 from the Korean Health and Care Technology R&D Project, Ministry for Health and Welfare, Republic of Korea to HJK.

**REFERENCES**

1. Wingergchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinsenker BG. The spectrum of neuromyelitis optica. *Lancet Neurol* 2007;6:805-815.

2. Allbutt T. On the ophthalmoscopic signs of spinal disease. *Lancet* 1870;1:76-78.

3. Devic E. Myelite subaigue compliquee de nevrite optique. *Bull Med (Paris)* 1894;8:1033-1034.

4. Lennon VA, Wingergchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. *Lancet* 2004;364:2106-2112.

5. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hison SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. *J Exp Med* 2005;202:473-477.

6. Wingergchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinsenker BG. Revised diagnostic criteria for neuromyelitis optica. *Neurology* 2006;66:1485-1489.

7. Matiello M, Jacob A, Wingergchuk DM, Weinsenker BG. Neuromyelitis optica. *Curr Opin Neurol* 2007;20:255-260.

8. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. *J Neurol* 2009;256:35-44.

9. Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. *J Neurol Sci* 2009;286:58-61.

10. Bizzoco E, Lollì F, Repice AM, Hakti B, Falcini M, Barilaro A, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. *J Neurol* 2009;256:1891-1898.

11. Kira J. Multiple sclerosis in the Japanese population. *Lancet Neurol* 2003;2:117-127.

12. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. *Neurology* 2004;63:2039-2045.

13. Pappas-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, de Almeida AM, Oliveira S, Basilio De Oliveira CA, et al. Optic neuromyelitis syndrome in Brazilian patients. *J Neurol Neurosurg Psychiatry* 2002;73:429-435.

14. Wingergchuk DM, Hoggancamp WF, O’Brien PC, Weinsenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). *Neurology* 1999;53:1107-1114.

15. de Seze J, Lebrun C, Stojkovic T, Fernity D, Chatel M, Vermersch P. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. *Mult Scler* 2003;9:521-525.

16. Davis R, Thiele E, Barney P, Riviello JJ. Neuromyelitis optica in childhood: case report with sequential MRI findings. *J Child Neurol* 1996;11:164-167.

17. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. *Neurology* 2008;70:344-352.

18. McKeon A, Lennon V A, Lotze T, Tenembaum S, Ness JM, Rensel M, et al. CNS aquaporin-4 autoimmunity in children. *Neurology* 2008;71:93-100.

19. Filley CM, Sternberg PE, Norengen MD. Neuromyelitis optica in the elderly. *Arch Neurol* 1984;41:670-672.

20. McAlpine D. Familial neuromyelitis optica: its occurrence in identical twins. *Brain* 1938;61:430-438.

21. Chi’en LT, Medeiros MO, Belloumini JJ, Lemni H, Whitaker JN. Neuromyelitis optica (Devic’s syndrome) in two sisters. *Clin Electroencephalography* 1982;13:36-39.

22. Yamakawa K, Kuroda H, Fujihara K, Sato S, Nakashima I, Takeda A, et al. Familial neuromyelitis optica (Devic’s syndrome) with late onset in Japan. *Neurology* 2000;55:318-320.

23. Keegan M, Weinsenker B. Familial Devic’s disease. *Can J Neurol Sci* 2000;27:557-558.

24. Cabrera-Gómez JA, Ramón-Pérez L, Saiz A, Llerena-Fernández P, Fernández-Fernández L, Ercilla G, et al. Neuromyelitis optica and multiple sclerosis in siblings. *Mult Scler* 2009;15:269-271.

25. Matiello M, Kim HP, Kim W, Bum DG, Barreira AA, Kingsbury DJ, et al. Familial neuromyelitis optica. *Neurology* 2010;75:310-315.

26. Yamakawa K, Horaiuchi I, Minohara M, Kawano Y, Ohyagi Y, Yamada T, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. *Brain* 1999;122:1689-1696.

27. Ito H, Yamakawa K, Kawano Y, Horaiuchi I, Yun C, Nishimura Y, et al. HLA-DP-associated susceptibility to the optico-spinal form of mul-
multiple sclerosis in the Japanese. *Tissue Antigens* 1998;52:179-182.

28. Misu T, Fujihara K, Nakashima I, Miyazawa I, Okita N, Takase S, et al. Pure optic-spinal form of multiple sclerosis in Japan. *Brain* 2002; 125:2460-2468.

29. Wang H, Dai Y, Qiu W, Zhong X, Wu A, Wang Y, et al. HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese. *J Neuroimmunol* 2011;233:181-184.

30. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. *Brain* 2002;125:1450-1461.

31. Itoh T, Rai T, Kuwahara M, Ko SB, Uchida S, Sasaki S, et al. Identification of a novel aquaporin, AQP12, expressed in pancreatic acinar cells. *Biochem Biophys Res Commun* 2005;330:832-838.

32. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression. *Arch Neurol* 2006;63:964-968.

33. Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. *Nat Rev Neurosci* 2003;4:991-1001.

34. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. *J Neurosci* 1997;17:171-180.

35. Crane JM, Tajima M, Verkman AS. Live-cell imaging of aquaporin-4 diffusion and interactions in orthogonal arrays of particles. *Neuroscience* 2010;168:892-902.

36. Marnetto F, Hellias B, Granieri L, Frau J, Patanella AK, Nytrøva P, et al. Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. *J Neuroimmunol* 2009;217:74-79.

37. Mader S, Lutterotti A, Di Pauli F, Kuenz B, Schanda K, Aboul-Enein F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. *PLoS One* 2010;5:e10455.

38. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittcock SJ, Lucchinetti CF, et al. Neuromyelitis optica-IgG predicts relapse after longitudinally extensive transverse myelitis. *Ann Neurol* 2006;59:566-569.

39. Maticelo M, Lennon VA, Jacob A, Pittcock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. *Neurology* 2008;70:2197-2200.

40. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. *Brain* 2007;130:1235-1243.

41. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. *Brain* 2008;131:3072-3080.

42. Kim HJ, Li XF, Kim W, Kim SH, Choi K, Lee JE, et al. Quantitative measurement of anti-aquaporin-4 antibody by enzyme-linked immunosorbent assay using purified human aquaporin-4. [abstract P60]. *Proceedings of 4th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis*. Singapore, 2010;1290.

43. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. *Brain* 2007;130:1224-1234.

44. Hinson SR, Pittcock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extra-cellular domain in neuromyelitis optica. *Neuroreport* 2009;20:508-512.

45. Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. *J Immunol* 2008;181:5730-5737.

46. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itayama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. *Neurology* 2010;75:208-216.

47. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chambers JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. *J Exp Med* 2008;205:2473-2481.

48. Marignier R, Giraudon P, Vukusic S, Confavreux C, Homorat J. Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications. *Ther Adv Neurol Disord* 2010;3:311-321.

49. Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. *Biochem Biophys Res Commun* 2009;386:623-627.

50. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. *Brain* 2010;133:349-361.

51. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica pathology of patient immunoglobulin in vivo. *Ann Neurol* 2009;66:630-643.

52. Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupre C, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. *Ann Neurol* 2009;66:617-629.

53. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. *Acta Neuropathol* 2010;120:223-236.

54. Kalluri SR, Rothenhammer V, Staszewski O, Srivastava R, Petermann F, Prinz M, et al. Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. *PLoS One* 2011;6:e16083.

55. Jarius S, Franciotta D, Bargamasi R, Wildemann B, Wandinger KP. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. *Clin Chem Lab Med* 2010;48:659-663.

56. Pittcock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non-organ-specific autoimmunity. *Arch Neurol* 2008;65:78-83.

57. Pittcock SJ, Weinshenker BG, Wingerchuk D, Lucchinetti CF, Lennon VA. Autoimmune neurological accompaniments of neuromyelitis optica (NMO). *Ann Neurol* 2006;60:541.

58. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. *Eur J Neurol* 2006;13:655-658.

59. Kister I, Gulati S, Boz C, Bargamasi R, Piccolo G, Oger J, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. *Arch Neurol* 2006;63:851-856.

60. Antoine JC, Cambessèché JP, Absi L, Lassablière F, Féasson L. Devic disease and thymoma with anti-central nervous system and anti-thymus antibodies. *Neurology* 2004;62:978-980.

61. Magaña SM, Pittcock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. NMO-IgG status in fulminant CNS inflammatory demyelinating disorders (IDD). *Neurology* 2007;68:A160. Abstract.

62. Mandler RN. Neuromyelitis optica Devic’s syndrome, update. *Autoimmun Rev* 2006;5:537-543.

63. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. *Neurology* 2003;60:848-853.

64. Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorders. *Mult Scler* 2011;17:1107-1112.

65. Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. *Pediatrics* 2008;122:...
New Insights into NMO

e1039-e1047.

68. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-1482.

69. Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146.

70. Kato S, Mori M, Makino T, Hayakawa S, Kusuhara S. "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009;66:425-428.

71. Kim JE, Kim SM, Ahn SW, Lim BC, Chae JH, Hong YH, et al. Brain abnormalities in neuromyelitis optica. J Neurol Sci 2011;302:43-48.

72. Saiki S, Ueno Y, Moritani T, Sato T, Sekine T, Kawajiri S, et al. Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol 2009;284:217-219.

73. Magaña SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-717.

74. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006;210:307-313.

75. Tanaka Y, Kimura K, Kawachi I, Imazuka T. No relapse of neuromyelitis optica during drug-induced B-lymphopenia with hypogammaglobulinemia. Neurology 2010;75:1745-1747.

76. Matsuoka T, Matsuhashi T, Kawano Y, Oosegawa M, Ochi H, Ishizu T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007;130:1206-1223.

77. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007;4:e133.

78. Hayakawa S, Mori M, Okata A, Kamegawa A, Fujiyoshi Y, Yoshimura Y, et al. Neuromyelitis optica anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuromyelitis Optica 2008;16:181-187.

79. Fazio R, Malosio ML, Lampasona V, De Feo D, Privitera D, Marneto F, et al. Antiaquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler 2009;15:1153-1163.

80. Bergamaschi R, Tonietti S, Franciotta D, Candelo E, Tavazzi E, Piccolo G, et al. Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 2004;10:2-4.

81. Zaffaroni M. Italian Devic’s Study Group. Cerebrospinal fluid findings in Devic’s neuromyelitis optica. Neurol Sci 2004;25:S368-S370.

82. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118:209-217.

83. Miller DH, Weinschenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-1174.

84. Chan KH, Tsang KL, Fong GC, Cheung RT, Ho SL. Idiopathic severe recurrent transverse myelitis: a restricted variant of neuromyelitis optica. Clin Neurology Neurosurgery 2005;107:132-135.

85. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003;126:276-284.

86. Sellner J, Bogdáld M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019-1032.

87. Bennetto L, Totham A, Healy P, Massey E, Scolding N. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol 2004;251:1515-1521.

88. Lehmahn HC, Hartung HP, Hetzel GR, Stieve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006;63:930-935.

89. Narita YM, Hiraoka K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011;38:236-245.

90. Weinschenker BG, O’Brien PC, Pettersson TM, Noseworthy JH, Lucchetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886.

91. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinschenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146.

92. Luffriu S, Castillo J, Blanco Y, Ramis-Torrenté L, Rio J, Viàles M, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009;73:949-953.

93. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

94. Munemoto M, Otaki Y, Kasmasa S, Nanami M, Tokuyama M, Yahiho M, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-132.

95. Bornman M, Valentino R, Olindo S, Medhaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15:487-492.

96. Luffriu S, Castillo J, Blanco Y, Ramis-Torrenté L, Rio J, Viàles M, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009;73:949-953.

97. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

98. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

99. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

100. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

101. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

102. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

103. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

104. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

105. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

106. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

107. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.

108. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.
109. Hommes OR, Weiner HL. Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire. J Neurol Sci 2004;223:65-67.

110. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-1220.

111. La Mantia L, Mascoli N, Milanese C, Azathioprine. Safety profile in multiple sclerosis patients. Neurol Sci 2007;28:299-303.

112. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-974.

113. Ginzler EM, Aranow C, Merrill JT, Orloff K, Henry D. Toxicity and tolerability of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) in a multicenter trial as induction therapy for lupus nephritis (LN). Arthritis Rheum 2003;48:S647.

114. Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martin C. Sustained improvement of a girl affected with Devic’s disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford) 2006;45:913-915.

115. Jacob A, Matiello M, Weinstenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66:1128-1133.

116. Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther 2007; 20:229-238.

117. Fidler JM, DeJoy SQ, Smith FR 3rd, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol1986;136:2747-2754.

118. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957-963.

119. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011;68:473-479.

120. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004;63:S28-S32.

121. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009;15:505-508.

122. Bakker J, Metz L. Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004;31:265-267.

123. Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007;46:1671-1672.

124. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.

125. Jacob A, Weinsheker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.

126. Kim SH, Kim W, Li XF, Jung UJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011. [Epub ahead of print]

127. Ibrahim H, Dinmachie MM, Shahrani A. A review: the use of rituximab in neuromuscular diseases. J Clin Neuromuscul Dis 2010;12:91-102.

128. Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010;68:271-274.

129. Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009:13:505-508.